Should I Buy SMTI? SMTI 2026 Analysis

Should You Buy Sanara Medtech Inc (SMTI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

21.060

1 Day change

-1.50%

52 Week Range

37.500

Analysis Updated At

2026/01/26

Sanara MedTech Inc (SMTI) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company shows promising revenue growth projections and strong gross margins, its technical indicators, recent analyst downgrade, and lack of significant trading signals suggest a cautious approach. The stock's current pre-market price of $21.75 is near its key support level, and there are no immediate catalysts or strong bullish signals to justify an entry now.

Technical Analysis

The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 32.776, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its S1 support level of $21.636, with resistance at $23.213. Overall, the technical indicators suggest a bearish trend.

Options Data

Positive Catalysts

The company projects strong revenue growth for Q4 2025 (3%-5% YoY) and FY 2026 (13%-17% YoY). Gross margins are high at 90.56%, and the company anticipates significant sales growth in its BIASURGE Advanced Surgical Solution.

Neutral/Negative Catalysts

The company's net income and EPS remain negative despite YoY improvements. Analysts have recently lowered the price target from $54 to $36, reflecting tempered expectations. Technical indicators suggest bearish momentum, and there are no significant trading trends from hedge funds or insiders.

Financial Performance

In Q3 2025, revenue increased by 21.51% YoY to $26.3 million, and gross margin improved to 90.56%. However, net income remains negative at -$30.4 million, albeit showing a significant improvement of 964.16% YoY. EPS also remains negative at -3.52, up 935.29% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright recently lowered the price target from $54 to $36 but maintained a Buy rating, citing the company's plans for sustainable revenue growth and improved profitability.

1 Analyst Rating

Wall Street analysts forecast SMTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMTI is 36 USD with a low forecast of 36 USD and a high forecast of 36 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 21.380

Low

Averages

High

Current: 21.380

Low

Averages

High

H.C. Wainwright

Buy

downgrade

$54 -> $36

AI Analysis

2025-11-14

Reason

H.C. Wainwright

Price Target

$54 -> $36

AI Analysis

2025-11-14

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Sanara MedTech to $36 from $54 and keeps a Buy rating on the shares following the Q3 report. The company plans to execute its commercial plan and improve operational efficiency to support sustainable revenue growth and improved profitability going forward, the analyst tells investors in a research note.

H.C. Wainwright

Yi Chen

Buy

maintain

$53 -> $54

2025-08-18

Reason

H.C. Wainwright

Yi Chen

Price Target

$53 -> $54

2025-08-18

maintain

Buy

Reason

H.C. Wainwright analyst Yi Chen raised the firm's price target on Sanara MedTech to $54 from $53 and keeps a Buy rating on the shares. The company reported a Q2 beat, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SMTI

Unlock Now

SMTI Should I Buy

SMTI Should I Buy

Should You Buy Sanara Medtech Inc (SMTI) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch